halcinonide and Skin-Diseases

Data were reviewed on the beneficial responses and adverse reactions among 2,849 patients in 14 paired-comparison studies with eight unoccluded topical corticosteroids in six steroid-responsive dermatoses. Adverse reactions were found to be mild, transient, and, for the most part, rare. Of 5,698 treatment exposures, 249 (4.39%) adverse reactions were reported, including irritation (1.3%), itching (0.95%), burning (0.81%), dryness (0.46%), scaling (0.30%), and vesicle formation (0.16%). Other reactions occurred in less than one in 1,000 treatment exposures. No severe reactions were observed. Five subjects (0.17%) terminated treatment early because of adverse reactions. The incidence of adverse reactions to vehicle alone was 6.7%. The benefit-risk ratio for mild reactions was 17:1. Therefore, long lists of adverse reactions are inappropriate in written consent forms for prospective volunteers for clinical trials. Al alternative warning statement is proposed.

Topics: Administration, Topical; Anti-Inflammatory Agents; Clinical Trials as Topic; Dermatitis, Atopic; Dermatitis, Contact; Double-Blind Method; Female; Fluocinonide; Glucocorticoids; Halcinonide; Humans; Male; Psoriasis; Skin Diseases

A comparative trial between betamethasone valerate and halcinonide has shown the former to be superior, thus contradicting the results from other trials. It is thought that the discrepancy is due to differences in the nature of the preparations used in the various studies. It is suggested that note is made of the base used in trials before final conclusions about the efficicacy of steroids are made.

Topics: Administration, Topical; Betamethasone; Betamethasone Valerate; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Eczema; Halcinonide; Humans; Ointments; Psoriasis; Skin Diseases

Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Glucocorticoids; Halcinonide; Humans; Male; Ointments; Pregnadienediols; Pregnenediones; Skin Diseases

The efficacy of halcinonide cream, 0.1 percent, was evaluated in 101 patients with moderate or severe dermatoses. Conditions of these patients included contact dermatitis, atopic dermatitis, nummular eczema, neurodermatitis, stasis dermatitis, dyshidrosis, and various combinations of these disorders. Halcinonide cream was prescribed twice or three times a day for three weeks, and patients were followed-up weekly during this period. Sixteen patients stopped treatment after two weeks because their lesions had cleared. By the end of three weeks, the condition in 46 of the patients had completely resolved, the condition in 39 showed marked improvement, the condition in 10 had improved moderately, the condition in 5 showed mild improvement, and the condition in 1 did not show any improvement. No local or systemic side effects were reported. We conclude that halcinonide cream is an effective and safe topical therapy in the short-term treatment of a variety of moderate to severe steroid-responsive dermatoses.

Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Female; Follow-Up Studies; Halcinonide; Humans; Infant; Male; Middle Aged; Pregnenediones; Skin Diseases

Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Eczema; Erythema; Female; Halcinonide; Humans; Lichen Planus; Male; Middle Aged; Ointments; Parapsoriasis; Pityriasis; Pregnenediones; Psoriasis; Skin Diseases